CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Renovaro Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Renovaro Inc
Century City Medical Plaza
2080 Century City East, Suite 906
Phone: (212) 763-0184p:212 763-0184 LOS ANGELES, CA  90067  United States Ticker: RENBRENB
Business Summary
Renovaro Inc. specializes in cancer diagnostics and therapeutics powered by artificial intelligence (AI). The Company operates through two subsidiaries: Renovaro Biosciences, Inc. (Renovaro Biosciences) and Renovaro Cube. Renovaro Biosciences is a biotechnology company intending to develop advanced allogeneic cell and gene therapies to promote stronger immune system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers, and potentially to treat or cure serious infectious diseases such as Human Immunodeficiency Virus (HIV) infections. Renovaro Cube is an AI-driven healthcare technology company focusing on the earliest possible detection of cancer and its recurrence. Renovaro Cube has developed an AI platform that analyzes genetics using Explainable AI to provide earlier and more accurate cancer diagnosis. This platform uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20246/30/2024YesYes--Yes

Industries
SIC Code Description
6770 Blank checks
8731 Commercial physical and biological research
7372 Prepackaged software

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Mauricevan Tilburg 53 10/14/2024 10/14/2024
Chief Executive Officer, Director DavidWeinstein 64 10/14/2024 10/14/2024
Chief Financial Officer NathenFuentes 42 1/6/2025 1/6/2025
3 additional Officers and Directors records available in full report.

Business Names
Business Name
DDRT
ENOB
GEDi Cube B.V.
7 additional Business Names available in full report.

General Information
Number of Employees: 25 (As of 6/30/2024)
Outstanding Shares: 158,717,342 (As of 11/11/2024)
Shareholders: 197
Stock Exchange: NASD
Federal Tax Id: 452559340
Fax Number: (845) 818-3588


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, January 28, 2025